HPHA Stock Overview
A biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Heidelberg Pharma AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €2.86 |
52 Week High | €4.07 |
52 Week Low | €2.63 |
Beta | -0.36 |
1 Month Change | -4.03% |
3 Month Change | -5.61% |
1 Year Change | -23.94% |
3 Year Change | -59.94% |
5 Year Change | 0.70% |
Change since IPO | -94.59% |
Recent News & Updates
Recent updates
Is Heidelberg Pharma (ETR:HPHA) A Risky Investment?
Feb 16Heidelberg Pharma AG's (ETR:HPHA) Price In Tune With Revenues
Dec 05Industry Analysts Just Upgraded Their Heidelberg Pharma AG (ETR:HPHA) Revenue Forecasts By 21%
Jul 21Analyst Forecasts For Heidelberg Pharma AG (ETR:HPHA) Are Surging Higher
Oct 16Heidelberg Pharma (ETR:HPHA) Will Have To Spend Its Cash Wisely
Nov 28Heidelberg Pharma AG (ETR:HPHA) Analysts Are More Bearish Than They Used To Be
Mar 27We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully
Mar 15Investors Who Bought Heidelberg Pharma (ETR:HPHA) Shares Five Years Ago Are Now Up 245%
Jan 17We Think Heidelberg Pharma (ETR:HPHA) Needs To Drive Business Growth Carefully
Dec 14Shareholder Returns
HPHA | DE Biotechs | DE Market | |
---|---|---|---|
7D | -0.7% | -2.7% | -3.1% |
1Y | -23.9% | -24.2% | -0.5% |
Price Volatility
HPHA volatility | |
---|---|
HPHA Average Weekly Movement | 2.5% |
Biotechs Industry Average Movement | 4.2% |
Market Average Movement | 5.0% |
10% most volatile stocks in DE Market | 10.3% |
10% least volatile stocks in DE Market | 2.5% |
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 98 | Andreas Pahl | heidelberg-pharma.com |
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. The company is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for the treatment of gastrointestinal tumors.
Heidelberg Pharma AG Fundamentals Summary
HPHA fundamental statistics | |
---|---|
Market cap | €133.29m |
Earnings (TTM) | -€18.28m |
Revenue (TTM) | €9.05m |
14.7x
P/S Ratio-7.3x
P/E RatioIs HPHA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
HPHA income statement (TTM) | |
---|---|
Revenue | €9.05m |
Cost of Revenue | €1.83m |
Gross Profit | €7.22m |
Other Expenses | €25.50m |
Earnings | -€18.28m |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
Jul 11, 2024
Earnings per share (EPS) | -0.39 |
Gross Margin | 79.75% |
Net Profit Margin | -201.94% |
Debt/Equity Ratio | 11.2% |
How did HPHA perform over the long term?
See historical performance and comparison